Discordant cellular response to pre-surgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification

We describe herein a patient presenting with bilateral ER+ breast tumors who was enrolled in a clinical trial exploring molecular aberrations associated with hormone-refractory tumor cell proliferation. Short-term (2-week) hormonal therapy with the aromatase inhibitor letrozole substantially reduced...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Balko, Justin M., Mayer, Ingrid A., Sanders, Melinda E., Miller, Todd W., Kuba, Maria G., Meszoely, Ingrid M., Wagle, Nikhil, Garraway, Levi A., Arteaga, Carlos L.
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3682668/
https://ncbi.nlm.nih.gov/pubmed/22879364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-12-0511
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items